Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF)-2020- A DelveInsight Report

According to DelveInsight researchers, the Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and

dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight Business Research

+91-11-4568 9769

info@delveinsight.com

Fatty Acid Amide Hydrolase (FAAH) Inhibitors – Pipeline Insights, 2015 – A DelveInsight’s Report

Fatty acid amide hydrolase (FAAH) is an intracellular amidase signature family of serine hydrolases enzyme, which catalyzes the hydrolysis of bioactive fatty acid ethanolamides such as anandamide and oleoylethanolamide. FAAH serves as the major metabolic regulator of many of the endogenous fatty acid amides, exhibiting a distribution consistent with its role in terminating their effects at the released sites of action. It is the only well characterized mammalian enzyme bearing their unusual Ser–Ser–Lys catalytic triad.

A remarkable series of potent, selective, and efficacious inhibitors of the enzyme FAAH have now been disclosed, many of which have been utilized to mechanistically and structurally characterize the enzyme. In this regard, it is interesting to note that around 70 million Americans annually suffer from chronic disorders in sleep, making sleep second only to pain in the number of patients seeking medical attention.

Several studies summarized in recent reviews have detailed the discovery of FAAH and defined its potential to serve as a new therapeutic target for the treatment of a range of clinical disorders. The development of inhibitors of FAAH, the enzyme responsible for degradation of endogenous oleamide and anandamide and may prove to be useful therapeutic agents for the treatment of sleep disorders and pain.

Since FAAH is recognized as a drug target, a large number of inhibitors have been synthesized and tested since 1994, and these are reviewed in terms of reversibility, potency, and specificity for FAAH and cannabinoid receptors. An innovative clinical opportunity likely will emerge, from better understanding the fundamental physiological role of the signaling fatty acid amides, which FAAH regulates. This area is still incompletely defined.

Inhibitors of FAAH are considered a potential therapeutic approach, for the treatment of several nervous system disorders, including pain, anxiety, and insomnia. However, for FAAH inhibitors to achieve clinical utility, they must not only display efficacy in vivo but also selectivity for this enzyme relative to the numerous other serine hydrolases present in mammalian proteomes.

Featured image

Figure 1: Mechanism of Fatty Acid Amide Hydrolase

“The FAAH Inhibitors – Pipeline Insights, 2015” report, provides information of 25+ pipeline drugs with 13+ companies actively involved in drug development. There are 3 drugs in phase II, 2 in phase I, 4 in pre-clinical, 1 in discovery, 14 in inactive and 1 in discontinued. Vernalis plc is developing a lead product V-158866 which is in Phase II.

DelveInsight has made strong presence in Orphan market, with 200+ Reports on Orphan based Indications, 100+ Reports on Oncology based Indications & Mechanism of Action (MOA), 70+ Reports on CVS Indications, 60+ Reports on CNS Indications and 15+ Reports on Specialized Gene Therapy.

DelveInsight’s report provides Assessment over chemical, technology information and comparative analysis at various stages. In addition, FAAH Inhibitors – Pipeline Insights, 2015 report will help to identify the key players of market and the potential market movers and barriers.

DelveInsight’s FAAH Inhibitors – Pipeline Insights, 2015 report will help companies to optimize their portfolio by analyzing the market and creating effective counter-strategies for collaborations and licensing deals. Apart from this the report on FAAH Inhibitors – Pipeline Insights will provide the technologies in use that will allow the Pharma manufacturers to attain high production at competitive pricing. DelveInsight’s also provide custom research services in coherence with interest area of the clients.

DelveInsight is offering the Report at a price of USD 1,250 as a single user license, USD 2,500 as a site license and USD 4,000 as a Global/Enterprise License.

For more information on our FAAH Inhibitors – Pipeline Insights reports email us at info@delveInsight.com

About DelveInsight:

DelveInsight is a leading Business Consulting and Market Research Firm.  We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this, DelveInsight also deals in providing custom research services in coherence with interest area of the clients.